Full Press Release Details
NASHVILLE, Tenn., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the agenda for its upcoming Investor & Analyst Day on Friday, September 26, from 11:30 a.m. ET to 3 p.m. ET in New York. The event will also be webcast live and instructions for accessing the webcast are below.
Harrow’s Investor & Analyst Day will include a comprehensive overview of Harrow’s business, featuring presentations from the Company’s leadership team covering the full scope of Harrow’s commercial portfolio, pipeline, and long-term vision. In addition, the program will include presentations from renowned physician key opinion leaders, who will share real-world perspectives on evolving treatment paradigms, market dynamics, and the significant patient needs Harrow is addressing.
Featured Physician Speakers:
Preliminary Agenda
| Topic | Speaker |
| Welcome & Opening Remarks | Mike Biega, VP of IR and Communications |
| Harrow Overview & Vision | Mark L. Baum, Chief Executive Officer |
| Financial Update | Andrew Boll, President & Chief Financial Officer |
| Harrow's Pipeline Products | Amir Shojaei, PharmD, PhD, Chief Scientific Officer |
| MELT-300 Development Overview and Potential | Larry Dillaha, MD, CEO of Melt Pharmaceuticals |
| An Expert’s Perspective on Procedural Sedation | Maggie Jeffries, MD |
| Commercial Vision | Patrick Sullivan, Head of Commercial |
| VEVYE Overview | Maria Lloyd, VP of Dry Eye |
| An Expert's Perspective on Dry Eye & VEVYE | Paul Karpecki, OD |
| Patient Access & Affordability of Specialty Products | Prashanth Annavajjhala, MD, Chief of Staff to CEO |
| TRIESENCE Expansion + BYQLOVI | Chad Brines, VP of Surgical Portfolio |
| Retina Products Overview | Aly Harrison, VP of Retina Portfolio |
| An Expert's Perspective on IHEEZO | Raj Patel, MD |
| An Expert's Perspective on Biosimilars &TRIESENCE | Seenu Hariprasad, MD |
| ImprimisRx | John Saharek, CEO of ImprimisRx |
| Closing Remarks | Mark L. Baum, Chief Executive Officer |
| Q&A |
In-person attendance is open to invited research analysts and institutional investors. To register for the in-person event, please email Mike Biega atmbiega@harrowinc.com. All others are invited to watch the live video webcast.
Webcast: A live webcast and replay will be available at:https://www.harrow.com/investors/events
Materials:A copy of the slide presentation will be posted to the same page at the start of the event.
AboutHarrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visitharrow.com.
Forward-LookingStatements
This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks, including litigation matters, and other uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2024, subsequent Quarterly Reports on Form 10-Q, and other filings with the SEC. Such documents may be read free of charge on the SEC’s web site atsec.gov.Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.